USA flag logo/image

An Official Website of the United States Government

Unique Topical Treatment for UV-Induced Skin Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65419
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
CA103378
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
A152 ASTeCC Building Lexington, KY 40506-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Unique Topical Treatment for UV-Induced Skin Cancer
Agency: HHS
Contract: 1R43CA103378-01
Award Amount: $119,962.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this project is to develop a polymer-based vehicle for the topical delivery of caffeine to inhibit UV-induced skin cancer. Despite increased use of sun screen, skin cancer rates continue to rise. Recently, caffeine has been shown to inhibit carcinogenesis in murine models of UV-induced skin tumor formation. The polymer-based delivery system described in this proposal seeks to improve the efficacy and convenience of topically applied caffeine for this application. To achieve this goal, the following Specific Aims will be pursued: Aim 1. Formulate a Polymer-based Topical Delivery System Containing Caffeine Aim 2. Evaluate the Effect of Caffeine Delivered from the Polymer-based Vehicle on Ultraviolet Light-induced Skin Cancer Using a Mouse Model.

Principal Investigator:

Bakul M. Bhatt
2103080636
BDC@BIOEVCORP.COM

Business Contact:

Gregg Siegel
2103080636
GSIEGEL@BIODEVCORP.COM
Small Business Information at Submission:

BIOMEDICAL DEVELOPMENT CORPORATION
BIOMEDICAL DEVELOPMENT CORP 500 SANDAU, STE 200 SAN ANTONIO, TX 78216

EIN/Tax ID: 742330067
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No